CPHI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CPHI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-04-28), China Pharma Holding's Intrinsic Value: Projected FCF is $0.63. The stock price of China Pharma Holding is $0.345. Therefore, China Pharma Holding's Price-to-Intrinsic-Value-Projected-FCF of today is 0.6.
The historical rank and industry rank for China Pharma Holding's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of China Pharma Holding was 1.80. The lowest was 0.20. And the median was 0.87.
The historical data trend for China Pharma Holding's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | 10.30 | 19.24 | 13.39 | 5.51 | 0.63 |
China Pharma Holding Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | 5.51 | 1.91 | 1.27 | 2.53 | 0.63 |
For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where China Pharma Holding's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Add all the Free Cash Flow together and divide 6 will get China Pharma Holding's Free Cash Flow(6 year avg) = $0.08.
China Pharma Holding's Intrinsic Value: Projected FCF for today is calculated as
Intrinsic Value: Projected FCF | = | (Growth Multiple | * | Free Cash Flow (6 year avg) | + | Total Stockholders Equity (Dec23) | * | 0.8) | / | Shares Outstanding (Diluted Average) |
= | (9.5203515959648 | * | 0.08048 | + | 7.455 | * | 0.8) | / | 10.626 | |
= | 0.63 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding (OTCPK:CPHI) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
China Pharma Holding's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 0.345 | / | 0.63337077888606 | |
= | 0.54 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of China Pharma Holding's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Ke Deng | 10 percent owner | NO.17, JINPAN ROAD, SECOND FLOOR, HAIKOU F4 570216 |
Frank Waung | officer: Chief Financial Officer | 72 GREAT HILLS RD., SHORT HILLS NJ 07078 |
G Michael Bennett | director | 4/F, NO. 3 JINYUAN ROAD, DAXING DISTRICT INDUSTRIAL DEVELOPMENT A, BEIJING F4 102600 |
Yingwen Zhang | director | NO. 5, UNIT 1, BLDG. 4, NO. 14 XIN NAN ZHI RD., CHENGDU, SICHUAN F4 610041 |
Baowen Dong | director | NO.9, BLDG. 9, SOUTH PARK, NO. 24, SECTION 1, 1ST RING ROAD, CHENGDU, SICHUAN F4 610041 |
Heung Mei Tsui | director, 10 percent owner | FLAT F, 3RD FL., MAYSON GARDEN BLDG., 68 HING FAT ST., CAUSEWAY BAY, HONG KONG F4 XXXXX |
Zhilin Li | officer: President and CEO | 2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVINCE F4 570216 |
Jian Yang | officer: Secretary | NO. 1 HAOYUAN ROAD, XINHUA DISTRICT, HAIKOU, HAINAN PROVI F4 570216 |
Xinhua Wu | officer: CFO | 2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVI F4 570216 |
George L Diamond | 10 percent owner | 174 FM 1830, ARGYLE TX 76226 |
David F Brigante | 10 percent owner | 174FM 1830, ARGYLE TX 76226 |
Marat Rosenberg | 10 percent owner | 17 FM 1830, ARGYLE TX 76226 |
Halter Financial Investments Lp | 10 percent owner | 174 FM 1830, ARGYLE TX 76226 |
Halter Financial Investments Gp Llc | 10 percent owner | 174 FM 1830, ARGYLE TX 76226 |
Timothy P Halter | director, 10 percent owner, officer: CEO, President & CFO | 174 FM 1830, ARGYLE TX 76226 |
From GuruFocus
By PRNewswire PRNewswire • 03-02-2020
By PRNewswire PRNewswire • 11-12-2021
By PRNewswire PRNewswire • 06-09-2021
By PRNewswire PRNewswire • 09-21-2020
By PRNewswire PRNewswire • 04-19-2021
By PRNewswire PRNewswire • 06-22-2022
By PRNewswire PRNewswire • 12-28-2022
By PRNewswire PRNewswire • 12-15-2022
By PRNewswire PRNewswire • 09-11-2019
By PRNewswire PRNewswire • 07-02-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.